Jacobs Levy Equity Management
LAB icon

Jacobs Levy Equity Management’s Standard BioTools LAB Stock Holding History

Jacobs Levy Equity Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
+1,633,112
New +$1.54M ﹤0.01% 669
2020
Q4 		– Sell
-253,538
Closed -$1.88M – 1058
2020
Q3 		$1.88M Sell
253,538
-166,620
-40% -$1.15M 0.02% 531
2020
Q2 		$1.69M Buy
420,158
+41,748
+11% +$145K 0.02% 559
2020
Q1 		$961K Sell
378,410
-522,695
-58% -$1.72M 0.01% 627
2019
Q4 		$3.14M Buy
901,105
+771,906
+597% +$2.72M 0.03% 460
2019
Q3 		$598K Buy
129,199
+97,000
+301% +$764K 0.01% 693
2019
Q2 		$397K Sell
32,199
-249,996
-89% -$3.18M 0.01% 776
2019
Q1 		$3.75M Buy
282,195
+52,100
+23% +$549K 0.05% 384
2018
Q4 		$1.98M Sell
230,095
-13,852
-6% -$108K 0.03% 463
2018
Q3 		$1.83M Sell
243,947
-11,345
-4% -$80.7K 0.03% 539
2018
Q2 		$1.52M Buy
255,292
+9,791
+4% +$55.8K 0.02% 558
2018
Q1 		$1.43M Buy
245,501
+4,300
+2% +$28.2K 0.02% 550
2017
Q4 		$1.42M Buy
241,201
+3,100
+1% +$17K 0.03% 541
2017
Q3 		$1.2M Buy
238,101
+36,850
+18% +$155K 0.02% 545
2017
Q2 		$813K Buy
201,251
+24,700
+14% +$117K 0.02% 603
2017
Q1 		$1M Buy
176,551
+120,251
+214% +$762K 0.02% 554
2016
Q4 		$410K Buy
56,300
+10,300
+22% +$64.7K 0.01% 717
2016
Q3 		$368K Hold
46,000
– – 0.01% 766
2016
Q2 		$415K Hold
46,000
– – 0.01% 804
2016
Q1 		$371K Buy
+46,000
New +$332K 0.01% 812

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Jacobs Levy Equity Management's LAB Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in Standard BioTools (LAB) in Q2 2026: 1,633,112 shares worth $1.34M. The stake represents ﹤0.01% of the portfolio and ranks #669 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in LAB as recently as Q3 2020.

Jacobs Levy Equity Management first reported a position in LAB in Q1 2016 and has held it in 20 quarters since. The position peaked at $3.75M in Q1 2019. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Jacobs Levy Equity Management held 1,633,112 shares of Standard BioTools worth $1.34M as of Q2 2026.
  • Standard BioTools was a new Jacobs Levy Equity Management position in Q2 2026.
  • Standard BioTools made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #669 holding.
  • Jacobs Levy Equity Management first reported a position in Standard BioTools in Q1 2016 and has held it in 20 quarters since.
  • Jacobs Levy Equity Management's Standard BioTools position peaked at $3.75M in Q1 2019.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.